WORCESTER, Mass., May 12, 2008 (PRIME NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that it has produced clinical samples of MetControl(tm), the Company's proprietary Metformin chewing gum product. These samples have been manufactured under GMP conditions and will be used in an upcoming trial, the results from which will allow the Company to proceed with additional R&D initiatives and consider regulatory agency registration applications. The protocol for the MetControl study is an open-label crossover study comparing MetControl and immediate release tablets in healthy volunteers.
